Stock Research: Mochida Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Mochida Pharmaceutical

TSE:4534 JP3922800002
89
  • Value
    100
  • Growth
    34
  • Safety
    Safety
    86
  • Combined
    94
  • Sentiment
    47
  • 360° View
    360° View
    89
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Mochida Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the production and sale of drugs. It operates in the Pharmaceutical-related segment, focusing on pharmaceutical products, and the Healthcare segment, dealing with quasi drugs and cosmetic products. The company also handles real estate brokerage and management, building maintenance, personal affairs agency, accounting, and purchasing businesses. It primarily operates in Japan. In the last fiscal year, the company had 1508 employees, a market cap of $720 million, profits of $359 million, and revenue of $701 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 89 (better than 89% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Mochida Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Mochida Pharmaceutical. The consolidated Value Rank has an attractive rank of 86, which means that the share price of Mochida Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 86% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 100. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 47. Professional investors are more confident in 53% other stocks. The consolidated Growth Rank also has a low rank of 34, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 66 of its competitors have better growth. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
86 86 88 81
Growth
34 28 5 9
Safety
Safety
100 100 61 61
Sentiment
47 24 18 54
360° View
360° View
89 75 45 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
20 20 20 n/a
Opinions Change
50 50 50 50
Pro Holdings
n/a 38 26 67
Market Pulse
39 20 24 35
Sentiment
47 24 18 54
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
86 86 88 81
Growth
34 28 5 9
Safety Safety
100 100 61 61
Combined
94 92 67 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
59 54 67 73
Price vs. Earnings (P/E)
81 83 83 82
Price vs. Book (P/B)
91 89 84 84
Dividend Yield
66 74 73 57
Value
86 86 88 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
34 12 9 14
Profit Growth
64 34 27 33
Capital Growth
20 33 27 18
Stock Returns
70 68 43 47
Growth
34 28 5 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
95 97 100 100
Refinancing
92 91 93 93
Liquidity
98 100 82 82
Safety Safety
100 100 61 61

Similar Stocks

Discover high‑ranked alternatives to Mochida Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Megmilk Snow Brand

TSE:2270
Country: Japan
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Tokuyama

TSE:4043
Country: Japan
Industry: Specialty Chemicals
Size: Medium
Full Stock Analysis

Daicel

TSE:4202
Country: Japan
Industry: Diversified Chemicals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.